Pirenzepine
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
ATC code | A02BX03 (WHO) |
Identifiers | |
| |
CAS Number | 28797-61-7 |
PubChem (CID) | 4848 |
IUPHAR/BPS | 328 |
DrugBank | DB00670 |
ChemSpider | 4682 |
UNII | 3G0285N20N |
KEGG | D08389 |
ChEBI | CHEBI:8247 |
ChEMBL | CHEMBL9967 |
ECHA InfoCard | 100.044.739 |
Chemical and physical data | |
Formula | C19H21N5O2 |
Molar mass | 351.403 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation.[1] It has no effects on the brain and spinal cord as it cannot diffuse through the blood–brain barrier.
Pirenzepine has been investigated for use in myopia control.[2][3]
It promotes the homodimerization or oligomerisation of M1 receptors.[4]
See also
References
- ↑ Stolerman, Ian P. (2 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 811. ISBN 978-3-540-68698-9. Retrieved 26 June 2013.
- ↑ Czepita D (2005). "Fundamentals of modern treatment of myopia". Ann Acad Med Stetin. 51 (2): 5–9. PMID 16519089.
- ↑ Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD (2011). "Interventions to slow progression of myopia in children". Cochrane Database Syst Rev (12): CD004916. doi:10.1002/14651858.CD004916.pub3. PMC 4270373. PMID 22161388.
- ↑ Pediani JD, Ward RJ, Godin AG, Marsango S, Milligan G (2016): "Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-Selective Antagonist Drugs." J Biol Chem. PMID 27080256